Volume Spike Investor (Free subscription) | yesterday
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was raised to overweight this morning by BGarclays as seen in our top ten analyst calls. Apparently, shares are taking it to heart immediately. At 8:18 AM EST we have seen 50,000 shares trade hands, yet shares are up over 10% at $13.80 after a $12.47 close. The average volume [...]
Stocks to Watch Today (Free subscription) | yesterday
Shares of $1.9 billion (market cap) drug maker Amylin (AMLN) are up 88 cents today, or 7%, at $13.35 after Barclay’s Capital analyst Jim Birchenough raised his rating on the stock to “Overweight” from “Equalweight” with a $22 price target, up from $16. Birchenough writes that his past concerns about the competitiveness [...]
Bio-IT World | Top Headlines (Free subscription) | 18/11/2009
November 10, 2009 | It was last year when Amylin CIO Steve Phillpott knew he had a space problem. With his two San Diego datacenters perilously close to capacity, housing close to 700 servers and about 200 Terabytes of data, he was contemplating building a third data center in Las Vegas or Phoenix. But the notion of enabling a virtual organization appealed to the IT industry veteran, hence he chose...
Forbes (Free subscription) | 05/11/2009
There's a lot of crossover between so-called obesity drugs and diabetes treatments. Amylin has both of them covered.
Xconomy (Free subscription) | 05/11/2009
TEDMED had Martha, Goldie, and other celebrity speakers, but San Diego-based Amylin Pharmaceuticals broke this week’s big news when it signed up a big Japanese partner to develop its line of obesity drugs. It’s all part of your regular dose of San Diego biotech news, and it’s ready now: —Amylin Pharmaceuticals, the San Diego-based diabetes drug [...]
Madd Money (Free subscription) | 03/11/2009
*E-Trade Financial, Penn National Gaming, Johnson & Johnson, Medco Health Solutions, Polo Ralph Lauren, Marvel Entertainment, MasterCard, Archer Daniels Midland, Amylin, Blockbuster Investors were given a hint of hope for recovery after retail brokerage *E-Trade Financial Corp. (NASDAQ: ETFC) stated in a recent regulatory filing that it had withdrew its application for additional funding through...
Fool.com (Free subscription) | 03/11/2009
It still has a big bet ahead of it, though.
PR News Wire (Free subscription) | 03/11/2009
CHICAGO, Nov. 3 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for COP, USB, CVS, AMLN, and NWL.
Indy Star (Free subscription) | 03/11/2009
Indianapolis -- Federal authorities have approved a synthetic hormone co-marketed by Eli Lilly and Co. and another pharmaceutical business for use without other medications.
San Diego Union (Free subscription) | 03/11/2009
Amylin Pharmaceuticals announced a deal under which Japan's Takeda Pharmaceutical will pick up a big chunk of the development cost for Amylin's weight-loss drugs.
Examiner (Free subscription) | 02/11/2009
Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co. on potential weight-loss treatments.
Click here to see all comments
<a href= http://www.toamazingstore.com >Cheap UGG Boots Free Shipping</a> <a href= http://www.toamazingstore.com/ugg-classic-cardy-boots-c-52.html >Cheap...
<a href= http://www.ugggoodsaler.com/ >cheap uggs</a> <a href= http://www.ugggoodsaler.com/ugg-classic-tall-boots-c-31.html >classic tall chestnut</a>...
<a href= http://www.nbashoesbuy.com/ >nba shoes shop </a> <a href= http://www.nbashoesbuy.com/nba-carmelo-anthony-shoes-c-488.html >NBA Carmelo Anthony...
SeekingAlpha.com (Free subscription) | 02/11/2009
Ruthanne Williams Roussel submits: Usually I don't dwell much on Amylin ( AMLN ), because with at least 15 sell-side analysts covering it and all kinds of press, I don't see that the investing community is clamoring for another opinion. However, as of Monday a few good little obesity calls do seem to be getting lost in the hullabaloo. Obesity Partnership For AMLN with Takeda Complete Story »...
cardiobrief.org (Free subscription) | 02/11/2009
Update-November 2- The FDA today updated its web page information for exenatide and issued its own press release about the revised label for Byetta. In sharp contrast to the Lilly/Amylin press statement (below), which emphasized the new first line monotherapy indication, the FDA focused on the renal warnings: “Health care professionals and patients taking Byetta should [...]
MarketIntelligenceCenter.com (Free subscription) | 02/11/2009
Amylin Pharmaceuticals (AMLN) leads the list of top gainers so far today and is now at $12.14, up $1.10 (9.96%) on volume of 12,236,203 shares traded. Over the last 52 weeks the stock has ranged from a low of $5.50 to a high of $15.69. The stock is seeing momentum today on news that it signed a deal with Japan's Takeda Pharmaceutical Co. on potential weight-loss treatments that could bring AMLN up...
The Street (Free subscription) | 02/11/2009
Japanese drugmaker Takeda licenses worldwide rights to Amylin weight-loss pipeline.
Videos